Department of Human Services
Division of Developmental Disabilities
Information Bulletin
DD.25.XXX
Purpose:
This information bulletin (IB) is meant to provide guidance on how to safely support an individual who uses non-insulin injectable treatments via pre-filled pens or auto-injectors for treatment of diabetes or obesity.
Background:
Public Act 103-0890 allows non-insulin injectable treatments via pre-filled pens or auto-injectors in settings governed by Rule 116 beginning January 1, 2025. This IB is temporary guidance meant to be used until Rule 116 can be amended to integrate the change in legislation.
Definitions:
Prefilled Pen: A device that comes preloaded with medication containing multiple doses of the medication.
Auto-Injector: A device filled with a single dose of medication. The device will inject the medication at a controlled rate after it is activated.
GLP-1 Receptor Agonist (Glucagon-Like Peptide-1 Receptor Agonist): Medication that helps with blood sugar control and weight loss by mimicking the GLP-1 hormone. This hormone is produced in the intestines and helps regulate blood sugar and appetite.
Process:
Prefilled pens or auto-injectors may be used in settings that are governed by Rule 116 when the following conditions are met:
- The individual is prescribed the medication by a licensed provider working within their scope of practice.
- The RN Trainer has to complete the Advanced Training for Injectable Treatments for Metabolic Glycemic Disorders.
- The RN Trainer then must present the Advanced Training for Injectable Treatments for Metabolic Glycemic Disorders to the authorized direct support professionals (ADSP).
- The ADSPs must pass the written test associated with the training.
- The ADSPs must then complete Competency-Based Training and Assessment (CBTA) process for delivering medications via prefilled pen or auto-injector for GLP-1.
Providers must reach out to the Bureau of Clinical Services to obtain the requisite trainings and testing materials by emailing DHS.ClinicalServices@illinois.gov.
Contact
For questions on this DRAFT IB, please email DHS.DDDComments@illinois.gov. Include "Non-Insulin Injectable Treatments via Pre-Filled Pen or Auto Injector" in the subject line.
Effective Date
March 1, 2025
